Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA in plantar fasciitis
NCT03137407Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plantar fasciitis comparing DAXI 240 U with Placebo (2 arms). Primary endpoint: Visual Analog Scale for Pain for the Foot at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
plantar fasciitis
Beyond the preview
Go deeper on NCT03137407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137407.